Koenderman L, Vrisekoop N
Cell Mol Immunol. 2024; 22(1):4-23.
PMID: 39653768
PMC: 11686117.
DOI: 10.1038/s41423-024-01244-9.
Fieni C, Ciummo S, Sorrentino C, Marchetti S, Vespa S, Lanuti P
Mol Ther. 2024; 32(11):3932-3954.
PMID: 39244641
PMC: 11573607.
DOI: 10.1016/j.ymthe.2024.09.011.
Gross N, Zhang Z, Mitchell J, Charmsaz S, Hernandez A, Coyne E
JCI Insight. 2024; 9(18).
PMID: 39106104
PMC: 11457845.
DOI: 10.1172/jci.insight.179292.
Goksen S, Varan G, Bilensoy E, Esendagli G
Mol Pharm. 2024; 21(9):4688-4699.
PMID: 39105761
PMC: 11372836.
DOI: 10.1021/acs.molpharmaceut.4c00663.
Qiu Y, Gao T, Smith B
Cancer Metastasis Rev. 2024; 43(4):1489-1510.
PMID: 38980581
PMC: 11900898.
DOI: 10.1007/s10555-024-10198-3.
The functional role of L-fucose on dendritic cell function and polarization.
Burton C, Bitaraf A, Snyder K, Zhang C, Yoder S, Avram D
Front Immunol. 2024; 15:1353570.
PMID: 38646527
PMC: 11026564.
DOI: 10.3389/fimmu.2024.1353570.
Tumor-specific activation of folate receptor beta enables reprogramming of immune cells in the tumor microenvironment.
Zhang F, Huang B, Utturkar S, Luo W, Cresswell G, Herr S
Front Immunol. 2024; 15:1354735.
PMID: 38384467
PMC: 10879311.
DOI: 10.3389/fimmu.2024.1354735.
Inflammatory Profile Assessment in a Highly Selected Athyreotic Population Undergoing Controlled and Standardized Hypothyroidism.
Piticchio T, Savarino F, Volpe S, Prinzi A, Costanzo G, Gamarra E
Biomedicines. 2024; 12(1).
PMID: 38275410
PMC: 10813236.
DOI: 10.3390/biomedicines12010239.
Inducible nitric oxide synthase (iNOS)-activated Cxcr2 signaling in myeloid cells promotes TGFβ-dependent squamous cell carcinoma lung metastasis.
Li X, Ke Y, Hernandez A, Yu J, Bian L, Hall S
Cancer Lett. 2023; 570():216330.
PMID: 37524225
PMC: 10530117.
DOI: 10.1016/j.canlet.2023.216330.
Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis.
Zhu L, Yu X, Cao T, Deng H, Tang X, Lin Q
Acta Pharm Sin B. 2023; 13(6):2464-2482.
PMID: 37425034
PMC: 10326251.
DOI: 10.1016/j.apsb.2023.03.004.
Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martinez-Ferrer M, Dorta-Estremera S, Dharmawardhane S
Front Oncol. 2023; 13:1152458.
PMID: 37397366
PMC: 10313121.
DOI: 10.3389/fonc.2023.1152458.
Neutrophils promote tumor invasion FAM3C-mediated epithelial-to-mesenchymal transition in gastric cancer.
Wang Y, Li X, Zhang T, Li F, Shen Y, He Y
Int J Biol Sci. 2023; 19(5):1352-1368.
PMID: 37056931
PMC: 10086748.
DOI: 10.7150/ijbs.79022.
Knocking-Down CD147/EMMPRIN Expression in CT26 Colon Carcinoma Forces the Cells into Cellular and Angiogenic Dormancy That Can Be Reversed by Interactions with Macrophages.
Feigelman G, Simanovich E, Brockmeyer P, Rahat M
Biomedicines. 2023; 11(3).
PMID: 36979746
PMC: 10044868.
DOI: 10.3390/biomedicines11030768.
From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies.
Alekseenko I, Kondratyeva L, Chernov I, Sverdlov E
Int J Mol Sci. 2023; 24(3).
PMID: 36769134
PMC: 9917659.
DOI: 10.3390/ijms24032796.
Myeloid cell reprogramming alleviates immunosuppression and promotes clearance of metastatic lesions.
Raghani R, Ma J, Zhang Y, Orbach S, Wang J, Zeinali M
Front Oncol. 2022; 12:1039993.
PMID: 36479083
PMC: 9720131.
DOI: 10.3389/fonc.2022.1039993.
Managing the TME to improve the efficacy of cancer therapy.
Bilotta M, Antignani A, Fitzgerald D
Front Immunol. 2022; 13:954992.
PMID: 36341428
PMC: 9630343.
DOI: 10.3389/fimmu.2022.954992.
Emerging Roles of Immune Cells in Cancer Development and Progression.
Entenberg D, Filippou P, Karagiannis G
Cancers (Basel). 2022; 14(11).
PMID: 35681622
PMC: 9179853.
DOI: 10.3390/cancers14112642.
Mini-Review: Can the Metastatic Cascade Be Inhibited by Targeting CD147/EMMPRIN to Prevent Tumor Recurrence?.
Rahat M
Front Immunol. 2022; 13:855978.
PMID: 35418981
PMC: 8995701.
DOI: 10.3389/fimmu.2022.855978.
Role of macrophages in tumor progression and therapy (Review).
Xu Y, Wang X, Liu L, Wang J, Wu J, Sun C
Int J Oncol. 2022; 60(5).
PMID: 35362544
PMC: 8997338.
DOI: 10.3892/ijo.2022.5347.
Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells.
Tian S, Welte T, Mai J, Liu Y, Ramirez M, Shen H
Front Pharmacol. 2022; 12:752934.
PMID: 35126104
PMC: 8814529.
DOI: 10.3389/fphar.2021.752934.